I-Mab Posts $(0.16) EPS; $9 PT Implies 371% Upside

For biotech investors, I-Mab's latest quarterly print is less about near-term losses and more about how the market is pricing a clinical-stage pipeline worth $220.89 million. The company's stock trades at $1.91, while H.C. Wainwright maintains a $9 price objective—a gap that either signals deep undervaluation or pipeline execution risk.

Two thinly covered micro-cap companies reported quarterly results in the third week of August 2026, and while neither commands broad attention, their data points reveal sharply different operating and risk profiles. I-Mab (NASDAQ:NBP), a clinical-stage oncology and immunology biotech, posted a quarterly loss per share of $(0.16), according to FiscalAI. CreditRiskMonitor.com (OTCMKTS:CRMZ), a subscription-based provider of corporate credit risk analytics, reported $(0.04) per share and $5.17 million in quarterly revenue, according to Zacks. I-Mab reported on Thursday, August 20, while CreditRiskMonitor reported on Wednesday, August 19, with both summaries circulating through newswires on Friday, August 21.

“

The stock opened at $2.00 on Friday, near its 12-month low of $1.98, and below both its 50-day ($2.16) and 200-day ($2.26) moving averages.

I-Mab's results fit the classic clinical-stage biotech profile: no reported revenue and a net loss, as resources flow into discovery, development and potential commercialization of antibody-based and protein biologic therapies for cancer and autoimmune disease. The stock opened Friday at $1.91, giving the company a market capitalization of $220.89 million. That valuation is modest relative to its 52-week high of $6.79, from which shares have fallen roughly 72%. The company's 50-day moving average sits at $1.77, suggesting the stock is trying to stabilize just above that near-term trend line. Its beta of 1.47 indicates elevated volatility compared with the broader market, consistent with binary clinical catalysts and thin trading liquidity.

The analyst landscape is genuinely mixed in a way that underscores uncertainty. H.C. Wainwright reiterated a buy rating with a $9.00 price objective on Thursday, implying roughly 371% upside from the $1.91 open. Weiss Ratings, by contrast, upgraded the stock only from 'sell (e+)' to 'sell (d-)' on June 1, 2026—an improvement in internal grade but still a sell. MarketBeat's consensus arrives at a Hold with a $9.00 target, an average distorted by having exactly one buy and one sell. The presence of a new institutional position from Brooklyn Investment Group—12,715 shares valued at about $51,000 in the fourth quarter—is a small but notable signal, and 38.38% institutional ownership indicates some professional interest despite the stock's depressed price.

CreditRiskMonitor's quarter was profitable but only marginally so. Revenue of $5.17 million produced a net margin of 1.05% and return on equity of 1.74%. The company's market capitalization of $21.54 million and price-to-earnings ratio of 100.05 imply that the market is paying a very high multiple for a very small stream of net income. The stock opened at $2.00 on Friday, near its 12-month low of $1.98, and below both its 50-day ($2.16) and 200-day ($2.26) moving averages. A beta of 0.22 reflects the stock's low correlation to broad market swings—not unusual for a micro-cap with sparse trading and a subscription revenue model that buffers earnings volatility. Its FRISK score platform and real-time credit-event alerts serve a niche but durable customer base of financial institutions, corporations and supply chain professionals.